Molbio Diagnostics Eyes ₹200 Crore in IPO Amid Global Expansion

Molbio Diagnostics, a leader in molecular diagnostics, has announced plans to raise ₹200 crore through a fresh issuance of shares, aimed at bolstering its capital expenditures. Additionally, the company intends to reduce its promoter stake from 46.6% to 43% through a ₹740 crore offer for sale. The IPO is set to attract high-risk investors looking for long-term growth opportunities.

Global Reach and Revenue Boost

Founded in 2000, Molbio Diagnostics operates six manufacturing facilities across India and serves over 90 countries. The company has experienced substantial revenue growth, largely driven by its tuberculosis diagnostic test kits. The 'Truenat' platform, a portable diagnostics system, is designed for resource-limited settings and offers rapid, accurate test results, making it a key product in the company's portfolio.

Government health programs and international aid agencies account for more than 80% of Molbio's revenue. The company's top clients contribute over half of its earnings, highlighting a significant customer concentration risk. Despite this, Molbio's revenue from operations rose by 31.5% annually to ₹1,445.7 crore, with a net profit increase of 40.2% reaching ₹164.1 crore between FY24 and FY26.

Financial Performance and Market Position

Molbio's EBITDA grew 33.2% to ₹328.2 crore in the same period, with the EBITDA margin expanding to 22.6% in FY26 from 22% in FY24. The company's financial performance underscores its solid market position, though it faces competition in the broader healthcare diagnostics and medical device sectors.

The IPO's valuation reflects a price-earnings (P/E) multiple of up to 57, positioning Molbio alongside other prominent healthcare diagnostics companies like Poly Medicure, Dr. Lal PathLabs, Metropolis Healthcare, and Vijaya Diagnostic Centre, whose P/E multiples range between 54 and 81.

Strategic Collaborations and Future Prospects

Beyond diagnostics, Molbio offers radiology, digital pathology, and breast health screening solutions through its subsidiaries and strategic alliances. The company provides molecular testing solutions for over 30 diseases via 43 diagnostic assays, underscoring its comprehensive approach to healthcare diagnostics.

Molbio's strategic focus on innovation and global expansion positions it as a compelling option for investors with a high-risk appetite seeking exposure to the growing diagnostics sector. As the company continues to develop its product offerings and expand its international footprint, its IPO could serve as a catalyst for future growth.